NEW YORK (GenomeWeb) – Vela Diagnostics today announced the launch of its Sentosa SQ Colorectal Cancer next-generation sequencing panel, which has received the CE mark.
The panel supports clinical decision making by identifying 112 clinically relevant hot spot mutations and sequence variants in target regions in 11 genes.
The test is the second CE-IVD oncology assay from Vela, following the Sentosa SQ Melanoma Panel. In June 2014, the firm announced it planned to launch a series of next-generation sequencing oncology and virology panels.
In November, the firm listed its Sentosa automated sequencing system as a Class II medical device with the US Food and Drug Administration. The device is based on Thermo Fisher's Life Technologies Ion Torrent platform.
The firm also received CE marking for KRAS and MRSA PCR tests in the last year, which use the Sentosa SX101 nucleic acid extraction platform.